Scientists develop drug that re-programmes cells to fight cancer

Image
IANS Canberra
Last Updated : Jul 20 2017 | 1:28 PM IST

Australian researchers have developed a drug capable of reprogramming the immune system to fight cancer, it was announced on Thursday.

The landmark new therapy, developed by the Peter MacCallum Cancer Centre, involves removing immune cells from the body to genetically enhance them before putting them back in the body to fight cancer, Xinhua reports.

The form of immunotherapy has previously been effective in fighting blood cancers but lead scientists Phillip Darcy and Paul Beavis found a way to improve its effectiveness against solid tumours for the first time.

Darcy said that the enhanced immune cells, known as CAR T cells, have been ineffective against solid tumours which have been able to produce a metabolite called adenosine which destroys the cells.

Some tumours have even shown the ability to simply reverse the enhancements placed on the cells, making them revert to T cells which have little ability to combat the tumours.

"The suppressive tumour environment dampens down the ability of the immune cells so we needed to give the cells something extra to be able to work in those environments," Darcy told Australian media on Thursday.

Researchers successfully trialled a drug in mice that blocks the metabolite, allowing CAR T cells to effectively target tumours.

They are now planning to take the drug into phase one human trials.

--IANS

ksk/sac

Disclaimer: No Business Standard Journalist was involved in creation of this content

*Subscribe to Business Standard digital and get complimentary access to The New York Times

Smart Quarterly

₹900

3 Months

₹300/Month

SAVE 25%

Smart Essential

₹2,700

1 Year

₹225/Month

SAVE 46%
*Complimentary New York Times access for the 2nd year will be given after 12 months

Super Saver

₹3,900

2 Years

₹162/Month

Subscribe

Renews automatically, cancel anytime

Here’s what’s included in our digital subscription plans

Exclusive premium stories online

  • Over 30 premium stories daily, handpicked by our editors

Complimentary Access to The New York Times

  • News, Games, Cooking, Audio, Wirecutter & The Athletic

Business Standard Epaper

  • Digital replica of our daily newspaper — with options to read, save, and share

Curated Newsletters

  • Insights on markets, finance, politics, tech, and more delivered to your inbox

Market Analysis & Investment Insights

  • In-depth market analysis & insights with access to The Smart Investor

Archives

  • Repository of articles and publications dating back to 1997

Ad-free Reading

  • Uninterrupted reading experience with no advertisements

Seamless Access Across All Devices

  • Access Business Standard across devices — mobile, tablet, or PC, via web or app

More From This Section

First Published: Jul 20 2017 | 1:20 PM IST

Next Story